Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report published on Thursday morning.

Pulse Biosciences Price Performance

NASDAQ PLSE opened at $17.14 on Thursday. The stock’s fifty day moving average is $17.65 and its two-hundred day moving average is $16.36. Pulse Biosciences has a fifty-two week low of $6.59 and a fifty-two week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the business earned ($0.19) EPS.

Institutional Trading of Pulse Biosciences

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences during the 1st quarter worth about $88,000. Cetera Advisors LLC purchased a new stake in Pulse Biosciences in the 1st quarter valued at about $109,000. Bank of New York Mellon Corp lifted its position in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.